The deal with Shanghai Argo is likely to have a positive short-term impact on Novartis' stock as it represents a strategic expansion of their RNAi therapeutics portfolio, which is a growing area in biopharmaceuticals. The upfront payment indicates a significant commitment and the potential for future earnings from commercial sales could be viewed favorably by investors.